Akums Drugs & Pharmaceuticals Ltd
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
- Market Cap ₹ 9,008 Cr.
- Current Price ₹ 572
- High / Low ₹ 1,176 / 405
- Stock P/E 56.0
- Book Value ₹ 146
- Dividend Yield 0.00 %
- ROCE 16.4 %
- ROE 13.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 25.9% CAGR over last 5 years
Cons
- Company has a low return on equity of 13.7% over last 3 years.
- Earnings include an other income of Rs.124 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare Nifty 500 BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 683 | 737 | 837 | 1,162 | 1,287 | 1,444 | 1,312 | |
| 603 | 697 | 811 | 1,524 | 1,045 | 1,571 | 1,173 | |
| Operating Profit | 80 | 40 | 27 | -362 | 242 | -127 | 138 |
| OPM % | 12% | 5% | 3% | -31% | 19% | -9% | 11% |
| 58 | 66 | -195 | 58 | -48 | 75 | 124 | |
| Interest | 4 | 4 | 1 | 4 | 13 | 18 | 15 |
| Depreciation | 23 | 25 | 26 | 28 | 30 | 33 | 40 |
| Profit before tax | 112 | 76 | -195 | -335 | 150 | -103 | 208 |
| Tax % | 33% | 33% | -26% | 14% | 17% | 61% | 23% |
| 75 | 51 | -145 | -382 | 125 | -165 | 161 | |
| EPS in Rs | 636.94 | 391.05 | -1,118.18 | -53.37 | 8.77 | -11.56 | 10.23 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 4% |
| TTM: | -9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 34% |
| TTM: | 202% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 14% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 14 | 29 | 29 | 31 |
| Reserves | 841 | 711 | 566 | 171 | 283 | 115 | 2,275 |
| 51 | 36 | 41 | 140 | 146 | 226 | 46 | |
| 153 | 678 | 690 | 1,488 | 1,437 | 1,725 | 333 | |
| Total Liabilities | 1,046 | 1,426 | 1,298 | 1,814 | 1,894 | 2,095 | 2,685 |
| 237 | 242 | 244 | 253 | 272 | 317 | 359 | |
| CWIP | 0 | 1 | 1 | 1 | 16 | 9 | 54 |
| Investments | 4 | 65 | 149 | 141 | 139 | 139 | 366 |
| 806 | 1,118 | 903 | 1,419 | 1,466 | 1,631 | 1,906 | |
| Total Assets | 1,046 | 1,426 | 1,298 | 1,814 | 1,894 | 2,095 | 2,685 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -22 | 56 | 228 | 94 | 248 | 91 | ||
| -242 | -100 | -298 | -202 | -165 | -459 | ||
| 302 | 3 | 95 | 90 | -21 | 375 | ||
| Net Cash Flow | 38 | -42 | 25 | -18 | 62 | 8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 88 | 92 | 95 | 73 | 59 | 57 |
| Inventory Days | 93 | 96 | 67 | 85 | 91 | 68 | 92 |
| Days Payable | 60 | 85 | 63 | 120 | 82 | 69 | 100 |
| Cash Conversion Cycle | 118 | 99 | 96 | 61 | 82 | 58 | 49 |
| Working Capital Days | 103 | 138 | 100 | 37 | 40 | 43 | 48 |
| ROCE % | 10% | 8% | -71% | 79% | -16% | 16% |
Documents
Announcements
-
Intimation Of Approval Of Revised Notice Of Annual General Meeting ('AGM')
7 Jun - Revised AGM notice includes agenda for Independent Director appointment.
-
Intimation Of Appointment Of Additional Director (Non-Executive- Independent)
4 Jun - Appointment of Mr. Anil Amin as Independent Additional Director from June 4, 2025, for five years.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2 Jun - Akums FY25 Q4 earnings: flat revenue, 9% volume growth, EUR200M contract, INR300Cr capex planned.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
27 May - Audio recording of Q4 FY25 and FY25 earnings call shared on May 27, 2025.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 27 May
Concalls
-
Jun 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Sep 2024Transcript PPT REC
-
Nov 2023TranscriptNotesPPTREC
Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.